Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
22 participants
INTERVENTIONAL
2001-08-31
2003-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
anakinra
anakinra
anakinra
B
anakinra and PEGsTNF-R1
anakinra and PEG sTNF-R1
anakinra and PEG sTNF-R1
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
anakinra
anakinra
anakinra and PEG sTNF-R1
anakinra and PEG sTNF-R1
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Disease duration of no less than 12 weeks of diagnosis confirmed by physician and source documentation
* Disease duration \< 10 years
* Active RA at baseline as defined by a minimum of 6 or more swollen joints and 9 or more tender/painful joints (based on a 66/68-joint count excluding distal interphalangeal joints) at screening and baseline,
And
* C-reactive protein (CRP) \> 2 mg/dL at screening.
* Have active clinical synovitis in the knee as determined by the investigator based on clinical evaluation
* 18 years of age or older
* Men or non-pregnant (negative serum HCG at screening unless surgically sterile or postmenopausal), non-breast-feeding women may be enrolled. Females of childbearing potential and males must use adequate contraceptive precautions as determined by the principal investigator.
* Subjects that have taken any DMARD for less than 3 months must not have taken DMARDs within 4 weeks prior to screening. Subjects that have taken any DMARD for longer than 3 months must not have taken DMARDs within 6 months of screening.
* Subject's doses of NSAIDs and oral corticosteroids (10 mg/day of prednisone or equivalent) must have been kept stable for 4 weeks before screening
* Subjects must not have had intrarticular injections in the joint that will be arthroscoped for at least 3 months prior to screening.
Before any study specific procedure or screening is done, the subject or legally acceptable representative must give informed consent for participation in the study (see Section 12.2). Before buccal smears and blood samples are taken for genetic testing, the subject or legally acceptable representative must give informed consent for use of those samples for genetic testing (see Section 12.2).
Exclusion Criteria
* Disease duration \>10 years
* Diagnosed with the following:
Felty's syndrome
Advanced or uncontrolled Diabetes Mellitus (defined as: HbA1c \> 8%, peripheral neuropathy, renal/retinal involvement, or vascular disorders)
Malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix, within the past five years
Any other major chronic inflammatory disease or syndrome (e.g., psoriatic arthritis, spondyloarthropathy, inflammatory bowel disease, fibromyalgia that required treatment in the last year)
* Any uncontrolled, clinically significant systemic disease
* Pre-existing or recent onset central nervous system demyelinating disorders
* Significant hematologic abnormalities
* A history of drug or alcohol abuse within the previous 24 weeks
* Known to be hepatitis B surface antigen, hepatitis C virus or Human Immunodeficiency Virus positive
* Any disorder that compromises ability to give informed consent for participation in this study
* Is expected to require a major surgical operation while on study that would interfere with the collection of the required assessments.
* Has an infection requiring systemic anti-infective therapy, open wounds, or has developed frequent acute or chronic infections during the past 12 weeks.
* Prior active tuberculosis.
* Total white blood cell count \< 3.5 x 109/L at screening
* Neutrophil count of \< 2.5 x 109/L at screening
* Platelet count of \< 125 x 109/L at screening
* Hemoglobin \< 8.0 g/dL at screening
* Abnormal liver function tests (AST/ALT \> 1.5 x the upper limits of normal) at screening
* Abnormal renal function (serum creatinine \> 1.5 x the upper limits of normal) at screening
* Prior treatment with any protein-based TNF inhibitor (e.g. etanercept, infliximab, PEG sTNF-RI, D2E7)
* Prior treatment with anakinra
* Receiving or has received any investigational drug within the previous 16 weeks or within at least 5 half-lives of any investigational drug, whichever is greater (or is currently using an investigational device)
* Received any intra-articular injections (e.g.. corticosteroids, hyaluronate preparations) or systemic corticosteroid injections within 4 weeks before the screening visit
* Requires analgesia other than paracetamol, NSAIDs, codeine, oxycodone, propoxyphene, tramadol, hydrocodone, or the combinations of these products (or equivalents)
* Subject (men or women of childbearing potential) is not using adequate contraceptive precautions as determined by the principal investigator
* Known allergy to E coli-derived products
* Not available for follow-up assessments
* Concerns for the subject's compliance with the protocol procedures
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amgen Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Related Links
Access external resources that provide additional context or updates about the study.
Notice regarding posted summaries of trial results
To access clinical trial results information click on this link
FDA-approved Drug Labeling
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20000211
Identifier Type: -
Identifier Source: org_study_id